Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics

Taimur Sher, Kena C. Miller, David Lawrence, Amy Whitworth, Francisco Hernandez-Ilizaliturri, Myron S. Czuczman, Austin Miller, William Lawrence, Syed Ali Bilgrami, Raman Sood, Margaret T. Wood, Annemarie W. Block, Kelvin Lee, Asher Alban Chanan-Khan

Research output: Contribution to journalArticle

76 Scopus citations

Abstract

Patients with chronic lymphocytic lymphoma (CLL) with high-risk cytogenetics [del(11q)(q22.3) or del(17p)(p13.1)] have limited therapeutic options and their prognosis remains poor. This analysis was conducted to determine the clinical activity of lenalidomide in patients with high-risk disease. Relapsed/refractory patients with CLL enrolled in a phase II clinical trial who had del(11q)(q22.3) or del(17p)(p13.1) were included in this analysis. Patients received single agent lenalidomide for 21 days of the 4 week treatment cycle. The overall response rate among patients with high-risk cytogenetics was 38%, with 19% of patients achieving a complete response. Median progression-free survival was 12.1 months, which is higher than emonstrated with other agents in comparable patient populations. In addition, the estimated 2-year survival probability was 58%, demonstrating that the responses achieved with lenalidomide are durable, even in patients with CLL with high-risk disease with poor risk cytogenetics.

Original languageEnglish (US)
Pages (from-to)85-88
Number of pages4
JournalLeukemia and Lymphoma
Volume51
Issue number1
DOIs
StatePublished - Jan 1 2010

Keywords

  • Chronic lymphocytic leukemia
  • Fludarabine-refractory
  • High-risk cytogenetics
  • Lenalidomide

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics'. Together they form a unique fingerprint.

  • Cite this

    Sher, T., Miller, K. C., Lawrence, D., Whitworth, A., Hernandez-Ilizaliturri, F., Czuczman, M. S., Miller, A., Lawrence, W., Bilgrami, S. A., Sood, R., Wood, M. T., Block, A. W., Lee, K., & Chanan-Khan, A. A. (2010). Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leukemia and Lymphoma, 51(1), 85-88. https://doi.org/10.3109/10428190903406806